Healthcare Equipment and Supplies
Company Overview of Infraredx, Inc.
Infraredx, Inc. operates as a cardiovascular imaging medical device company. It offers diagnosis and treatment of coronary artery diseases. The company’s products include dual-modality near-infrared spectroscopy intravascular ultrasound (IVUS) true vessel characterization imaging systems for identifying lipid core coronary plaques, and providing structural plaque information with IVUS; and optical catheters that provides a high resolution image of the structure of the plaque, as well as associated accessories. It serves hospital sites in the United States and Europe. The company was formerly known as InfraReDx, Inc. and changed its name to Infraredx, Inc. in November, 2012. Infraredx, Inc. w...
34 Third Avenue
Burlington, MA 01803
Founded in 1998
Key Executives for Infraredx, Inc.
Chief Executive Officer, President and Director
Senior Vice President of Technology Innovation
Vice President of Product Development
Vice President of Research
Compensation as of Fiscal Year 2016.
Infraredx, Inc. Key Developments
InfraReDx Seeks Acquisitions
Dec 22 14
InfraReDx, Inc. has filed an IPO in the amount of $55 million. InfraReDx said, "We may use a portion of our net proceeds to acquire and invest in complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction and are not involved in negotiations to do so."
Infraredx Announces Research Collaboration with Massachusetts General Hospital to Explore New Generation of Cardiovascular Imaging Devices
Dec 16 14
Infraredx, Inc. announced a collaboration with Massachusetts General Hospital (MGH) and coronary imaging researcher, Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar, and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The TVC Imaging System is the only FDA-cleared technology capable of rapidly, specifically and reliably identifying lipid core plaques, which are known to complicate stenting procedures and are suspected to be the vulnerable plaques that cause most heart attacks, using NIRS, and providing vessel structure information using intravascular ultrasound (IVUS). The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries